Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.7K
Overview
33.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults.

Vaccines·2026
Same author

Infection, vaccination and risk of dementia: a proposed immunological model.

Frontiers in immunology·2026
Same author

One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand.

NPJ vaccines·2025
Same author

Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.

Lancet (London, England)·2025
Same author

Infant Responses to Primary Immunization Following Vaccination in Pregnancy With Varying Doses of Recombinant Acellular Pertussis Vaccine Alone or Combined With Tetanus-Diphtheria.

The Pediatric infectious disease journal·2025
Same author

System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans.

Nature immunology·2025

Related Experiment Video

Updated: Mar 22, 2026

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

17.0K

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.

Quentin Canelle1, Walthère Dewé1, Bruce L Innis1

  • 1a GSK Vaccines , Rixensart , Belgium.

Human Vaccines & Immunotherapeutics
|April 23, 2016
PubMed
Summary

This study compared antibody avidity in children who received two H1N1 vaccines, Pandemrix™ (D-Pan) and Aprepanrix™ (Q-Pan). No significant differences in antibody avidity were found between the vaccines, despite differing narcolepsy risks.

Keywords:
AS03ArepanrixH1N1Pandemrixantibodyavidityhemagglutininimmunogenicitynarcolepsyvaccine

More Related Videos

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

13.5K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.9K

Related Experiment Videos

Last Updated: Mar 22, 2026

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

17.0K
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

13.5K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.9K

Area of Science:

  • Immunology
  • Vaccinology

Background:

  • Retrospective studies indicated an increased narcolepsy risk in some European countries associated with the Pandemrix™ (D-Pan) H1N1 vaccine.
  • A similar risk was not observed with the Aprepanrix™ (Q-Pan) H1N1 vaccine in Canada.
  • Previous studies showed equivalent antibody responses (hemagglutination inhibition titers) between D-Pan and Q-Pan vaccines.

Purpose of the Study:

  • To investigate potential differences in antibody avidity between the D-Pan and Q-Pan vaccines.
  • To explore if antibody avidity could explain the differing narcolepsy risks observed with these H1N1 vaccines.

Main Methods:

  • A post-hoc analysis of a comparative immunogenicity trial involving children aged 3-9 years.
  • Serum samples from D-Pan and Q-Pan vaccinees were analyzed using surface plasmon resonance.
  • Measurement of IgG antibody binding to recombinant A(H1N1)pdm09 hemagglutinin, including association and dissociation kinetics (kd).

Main Results:

  • Both D-Pan and Q-Pan vaccines induced high antibody avidity with slow dissociation (kd ≤ 10(-4)/s).
  • No significant differences in antibody avidity parameters (association, dissociation levels) were observed between the D-Pan and Q-Pan vaccine groups.
  • Antibody association levels correlated with hemagglutination inhibition titers, but dissociation levels did not.

Conclusions:

  • The study found no significant differences in antibody avidity between the Pandemrix™ (D-Pan) and Aprepanrix™ (Q-Pan) H1N1 vaccines in children.
  • Antibody avidity does not appear to be the differentiating factor for the observed differences in narcolepsy risk between these two vaccines.